All PDE enzyme activities were measured with a yittrium silicate based scintillation proximity assay that detects radioactive nucleotide monophosphates but not cyclic monophosphates. Assays are conducted in a total volume of 50 μl in 384 well plates (3706, Corning): comprised of 24 μl enzyme, 1 μl compound, and 25 μl of cyclic nucleotide. The general assay buffer consists of 50 mM Tris-HCl (pH 7.5) and 0.1% (w/v) bovine serum albumin (Fatty Acid Free, Sigma-Aldrich). Enzyme concentrations, substrate concentrations, and various PDE-specific buffer additives are described in Supplementary Table 1. Compounds to be tested are diluted in pure dimethyl sulfoxide (DMSO) using 10-point concentration-response curves, and 1 μl is acoustically dispensed into assay plates using the Echo555 (LabCyte). Maximal compound concentration in the reaction mixture is either 10 or 100 μM. Compounds at the appropriate concentration are pre-incubated with either of the PDE enzymes for 30 min before the reaction is started by the addition of substrate ([8-3H]-cAMP, 20.7 Ci/mmol or [8-3H]-cGMP; 6.5 Ci/mmol, Perkin Elmer). Reactions are allowed to proceed for 60 min at room temperature before quenching. Next, reactions are stopped by the addition of 400 μg/per well SPA beads (RPNQ0150, Perkin Elmer) and a potent non-selective PDE inhibitor to quench the reaction. Bead bound radioactivity (product) is quantified 12 h later a Microbeta counter (Perkin Elmer). Data is normalized to % inhibition using standard methods (Campbell et al., 2004), and IC50 values were plotted using PRISM (GraphPad Software) using the 4 parameter logistic equation (Campbell et al., 2004). Data for potency values are expressed as the geometric mean and arithmetic standard deviation.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.